Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at Elementary School Enrollment. Arch Dermatol. 2005. https://doi.org/10.1001/archderm.141.1.71.

Article  PubMed  Google Scholar 

Huson SM, Compston DA, Harper PS. A genetic study of Von Recklinghausen neurofibromatosis in South East Wales. II. Guidelines for genetic counselling. J Med Genet. 1989. https://doi.org/10.1136/jmg.26.11.712.

Article  PubMed  PubMed Central  Google Scholar 

Fountain JW, Wallace MR, Bruce MA, Seizinger BR, Menon AG, Gusella JF, et al. Physical mapping of a translocation breakpoint in neurofibromatosis. Science. 1989. https://doi.org/10.1126/science.2543076.

Article  PubMed  Google Scholar 

Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Sci. 2021. https://doi.org/10.1038/s41436-021-01170-5.

Article  Google Scholar 

Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and Associated Clinical deficits. J Pediatr. 2011. https://doi.org/10.1016/j.jpeds.2011.04.008.

Article  PubMed  Google Scholar 

Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018. https://doi.org/10.1093/neuonc/noy067.

Article  PubMed  PubMed Central  Google Scholar 

Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014. https://doi.org/10.1002/ajmg.a.36466.

Article  PubMed  Google Scholar 

Yoo HK, Porteous A, Ng A, Haria K, Griffiths A, Lloyd A, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurol. 2023. https://doi.org/10.1186/s12883-023-03429-7.

Article  PubMed  PubMed Central  Google Scholar 

Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis. J Med Genet. 2002. https://doi.org/10.1136/jmg.39.5.311.

Article  PubMed  PubMed Central  Google Scholar 

Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2015.65.3576.

Article  PubMed  Google Scholar 

Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. Hum Pathol. 2017. https://doi.org/10.1016/j.humpath.2017.05.010.

Article  PubMed  PubMed Central  Google Scholar 

Kresbach C, Dottermusch M, Eckhardt A, Ristow I, Paplomatas P, Altendorf L, et al. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities. Neuro Oncol. 2023. https://doi.org/10.1093/neuonc/noad053.

Article  PubMed  PubMed Central  Google Scholar 

Beert E, Brems H, Daniëls B, Wever I, De CF, Van, Schoenaers J, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011. https://doi.org/10.1002/gcc.20921.

Article  PubMed  Google Scholar 

Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Skeletal Radiol. 2020. https://doi.org/10.1007/s00256-019-03290-1.

Article  PubMed  Google Scholar 

Carton C, Gareth D, Blanco I, Friedrich RE, Ferner RE, Farschtschi S et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1 on behalf of the ERN GENTURIS NF1 Tumour Management Guideline Group. 2023; https://doi.org/10.1016/j.eclinm.2022.101818

Well L, Salamon J, Kaul MG, Farschtschi S, Herrmann J, Geier KI, et al. Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. Neuro Oncol. 2019. https://doi.org/10.1093/neuonc/noy199.

Article  PubMed  Google Scholar 

Demehri S, Belzberg A, Blakeley J, Fayad LM. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol. 2014. https://doi.org/10.3174/ajnr.A3910.

Article  PubMed  PubMed Central  Google Scholar 

Sung Yun J, Hee Lee M, Min Lee S, Seok Lee J, Jung Kim H, Joo Lee S, et al. Peripheral nerve sheath tumor: differentiation of malignant from benign tumors with conventional and diffusion-weighted MRI. Eur Radiol. 2021. https://doi.org/10.1007/s00330-020-07234-5.

Article  Google Scholar 

Koike H, Nishida Y, Ito S, Shimoyama Y, Ikuta K, Urakawa H, et al. Diffusion-weighted magnetic resonance imaging improves the accuracy of differentiation of Benign from malignant peripheral nerve sheath tumors. World Neurosurg. 2022;157:e207–14. https://doi.org/10.1016/j.wneu.2021.09.130.

Article  PubMed  Google Scholar 

Ahlawat S, Fayad LM. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: utility of the target sign by diffusion weighted imaging. Eur J Radiol. 2018. https://doi.org/10.1016/j.ejrad.2018.03.018.

Article  PubMed  Google Scholar 

Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology. 2019. https://doi.org/10.1212/WNL.0000000000008092.

Article  PubMed  Google Scholar 

Ristow I, Kaul MG, Stark M, Zapf A, Riedel C, Lenz A, et al. Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI. Neurooncol Adv. 2024. https://doi.org/10.1093/noajnl/vdae021.

Article  PubMed  PubMed Central  Google Scholar 

Reinert CP, Schuhmann MU, Bender B, Gugel I, la Fougère C, Schäfer J, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-018-4227-5.

Article  PubMed  Google Scholar 

Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, et al. Evaluation of intratumoural heterogeneity on 18F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2013. https://doi.org/10.1007/s00259-018-4227-5.

Article  PubMed  Google Scholar 

Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J, et al. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: Tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol. 2014. https://doi.org/10.1007/s00330-013-3020-x.

Article  PubMed  Google Scholar 

Derlin T, Tornquist K, Münster S, Apostolova I, Hagel C, Friedrich RE, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013. https://doi.org/10.1097/RLU.0b013e318266ce84.

Article  PubMed  Google Scholar 

Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, et al. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatr Blood Cancer. 2018. https://doi.org/10.1002/pbc.26733.

Article  PubMed  Google Scholar 

Bredella MA, Torriani M, Hornicek F, Ouellette HA, Palmer WE, Williams Z, et al. Value of PET in the assessment of patients with neurofibromatosis type I. Am J Roentgenol. 2007. https://doi.org/10.2214/AJR.07.2060.

Article  Google Scholar 

Brenner W, Friedrich RE, Gawad KA, Hagel C, Von Deimling A, De Wit M, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging. 2006. https://doi.org/10.1007/s00259-005-0030-1.

Article  PubMed  Google Scholar 

Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008. https://doi.org/10.1093/annonc/mdm450.

Article  PubMed  Google Scholar 

Ferner RE, Lucas JD, O’Doherty MJ, Hughes RAC, Smith MA, Cronin BF, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000. https://doi.org/10.1136/jnnp.68.3.353.

Article